GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET
Company Participants
Christian Dinneen-Long - General Counsel
Harout Semerjian - CEO
Edwin Rock - Chief Medical Officer
Bruce Johnson - Chief Commercial Officer
Brian Hahn - CFO
Conference Call Participants
Tara Bancroft - TD Cowen
Naureen Quibria - Capital One Securities
Edward White - H.C. Wainwright
Operator
Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to Christian Dinneen-Long, Company Counsel at GlycoMimetics. Please go ahead.
Christian Dinneen-Long
Good morning. Today, we will review our business updates and financial results for the quarter and year ended December 31, 2023. The press release we issued this morning is available on company's website at glycomimetics.com. This call is being recorded and a dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website.
On the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; Dr. Edwin Rock, Chief Medical Officer; and Bruce Johnson, Chief Commercial Officer.
Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidate, uproleselan and GMI-1687, the progress and timing of clinical trials being conducted by us or our collaborators including our expectations regarding data readout from those trials, planned or potential regulatory agency interactions or submissions, development plans and activities, prelaunch preparations and the company's cash position and runway.
Such statements represent management's judgment and intention as of today and involve assumptions, risks and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or through the GlycoMimetics website.
I'll now turn the call over to Harout.
Harout Semerjian
Thank you, Christian, and good morning, everyone. In 2023, we made great strides on the path towards becoming a commercial company. Building on the advances we made in 2023, I believe 2024 will be a transformational year for GlycoMimetics. In the second quarter of this year, we expect to report top line results from our Phase III trial of our lead drug candidate, uproleselan. This is a significant milestone that can fundamentally impact our company's trajectory, while potentially helping patients affected with relapsed and refractory acute myeloid leukemia to live longer.